Calculate PSA density from total PSA and prostate volume, review free/total PSA ratio, and compare the result with age-specific and simple BPH-context reference ranges.
PSA density (PSAD) puts the PSA value in the context of prostate size. That matters because benign enlargement can raise PSA on its own, so the same PSA value may mean something different in a 25 cc gland than in an 80 cc gland. Dividing PSA by prostate volume gives a simple density number that can be reviewed alongside MRI findings, age, free PSA, and PSA trend.
This calculator computes PSAD from a direct prostate volume or from ellipsoid dimensions, shows a free/total PSA ratio if you have both values, and compares the result with age-specific and simple BPH-context reference ranges. The goal is not to replace urologic evaluation or turn one number into a biopsy decision. It is to keep the core PSA-context measures in one place so the result can be interpreted more carefully.
PSA density is most useful when total PSA by itself is hard to interpret. This page keeps PSA, gland volume, a simple BPH-context estimate, age-specific reference ranges, and the free/total ratio together so the PSA value can be reviewed in a more realistic clinical frame.
PSAD = Total PSA (ng/mL) / Prostate Volume (cc). Prostate Volume (ellipsoid) = Length × Width × Height × 0.523. BPH-expected PSA ≈ Volume × 0.066 ng/mL/cc. Free/Total PSA ratio = (Free PSA / Total PSA) × 100.
Result: PSAD = 0.150 ng/mL/cc, higher-density range, BPH-expected PSA = 2.6 ng/mL, PSA excess +3.4
With PSA 6.0 and prostate volume 40 cc, PSAD = 0.15. On this page that falls into the higher-density reference range, meaning the PSA is less easily explained by benign enlargement alone. The BPH-context estimate of 2.6 ng/mL leaves a substantial PSA excess, but MRI findings, PSA trend, medications, infection, and clinician assessment still matter before any next step is chosen.
Total PSA rises with cancer, but it also rises with prostate size. PSA density adjusts for gland volume, which is why it is especially helpful in the PSA "grey zone" and in men with clear BPH enlargement.
A PSA density above about 0.15 ng/mL/cc is commonly treated as a more concerning range, while lower values are more compatible with benign enlargement. The exact meaning still depends on MRI findings, free PSA, age, family history, prior biopsy history, and whether the prostate was recently irritated by infection or instrumentation.
The density calculation is only as good as the volume estimate. MRI and TRUS are generally better than rough estimates, and the result should be interpreted with the same lab assay used for the serial PSA trend.
Last updated:
This page calculates prostate-specific antigen density by dividing total PSA by prostate volume, with the option to derive volume from length, width, and height using the standard ellipsoid formula. It also shows a free/total PSA ratio when free PSA is entered, age-specific PSA reference bands, and a simple BPH-context PSA estimate based on gland volume. The density thresholds shown on the page are presented as risk-context bands only.
The result is not a stand-alone biopsy rule. PSA density, free PSA, MRI findings, prior biopsy history, medications such as 5-alpha-reductase inhibitors, infection, and clinician judgment all affect how the number should be interpreted.
Many pathways treat values around 0.15 ng/mL/cc as a more concerning range, especially when PSA is in the grey zone and MRI is equivocal. The point of the page is to show that context, not to turn 0.15 into a universal biopsy command.
Prostate volume is most accurately measured by MRI. Transrectal ultrasound (TRUS) is the traditional method. The prolate ellipsoid formula (L × W × H × 0.523) calculates volume from three dimensions.
Free PSA is the portion not bound to proteins. Lower free/total ratios can fit a more concerning pattern, while higher ratios can be more reassuring, but the ratio still has to be read with total PSA, prostate volume, imaging, and the rest of the workup.
No. PSA density supplements total PSA by adjusting for gland size. It is most helpful when the absolute PSA is hard to interpret because benign enlargement may be contributing.
PSA density is commonly used as one more risk-context factor when MRI is already part of the workup. It can help frame equivocal situations, but MRI findings, exam, family history, prior biopsy history, and clinician judgment still carry a lot of weight.
The prolate ellipsoid formula (L × W × H × π/6 ≈ 0.523) correlates well with planimetric MRI volumes for glands under ~80 cc. For very large or irregularly shaped prostates, MRI volumetry may be more accurate.